The FDA has suspended the biologics license for Ixchiq (Chikungunya Vaccine, Live), developed by Valneva, following new safety data indicating potential risks associated with its use. The decision, delivered via an FDA Safety Communication, immediately halts the vaccine’s distribution in the United States.
Ixchiq, approved in late 2023 as the first vaccine to protect against the mosquito-borne chikungunya virus, was seen as an important public health measure in regions where the disease is endemic. Chikungunya can cause debilitating joint pain and fever, and outbreaks have been increasing globally due to expanding mosquito populations. The vaccine, administered as a single dose of live-attenuated virus, was widely anticipated by clinicians and travelers seeking protection.
According to the FDA, recent post-marketing surveillance and follow-up safety assessments raised concerns about rare but serious adverse events among certain recipients. While the agency has not yet specified the rate or type of safety signals observed, it emphasized that patient safety is the priority in suspending the license. The FDA has instructed healthcare providers to immediately cease administration of Ixchiq and to report any adverse events to the Vaccine Adverse Event Reporting System (VAERS).
Valneva stated it is cooperating fully with regulators and conducting additional investigations to determine the cause and extent of the safety findings. The company emphasized that the overall benefit-risk profile of the vaccine had been favorable in clinical trials but affirmed its commitment to ensuring patient safety.
The FDA will convene an expert advisory committee to review the data and determine next steps regarding the vaccine’s future availability. Until then, the agency advises that individuals planning travel to areas with active chikungunya transmission speak with healthcare providers about alternative mosquito-bite prevention strategies.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!